Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
This clinical trial will be sponsored and conducted by the Italian Oncology Foundation FoRT and supported by Bristol Myers Squibb and OSE Immunotherapeutics. The study will explore the strategy of...
-
First-in-human study evaluating CoVepiT, a multi-variant T cell COVID-19 vaccine for people at risk and vulnerable populations.CoVepiT is a peptide-based vaccine aiming to induce CD8+T-cell-mediated...
-
BI 765063, a first-in-class SIRPα inhibitor on the SIRPα/CD47 “Don’t eat me” pathway, is under collaborative development with Boehringer Ingelheim.Data indicate BI 765063 was well tolerated and showed...
-
CoVepiT is a SARS-CoV-2 vaccine activating T cell defences through CD8 T cell multi-epitopes.CoVepiT epitopes* are selected from 11 viral protein targets designed to cover all initial and new emerging...
-
Agreement expands Veloxis’ product portfolio and the continued commitment to improving the lives of transplant patients.OSE Immunotherapeutics to receive up to €315 million in potential...
-
NANTES, France, April 06, 2021 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics (ISIN: FR0012127173; Mnemo: OSE) announced the first peer-reviewed publication on OSE-230, a novel and innovative approach...
-
CoVepiT is a SARS-COV-2 vaccine activating T cell defenses through CD8 T-cell multi-epitope* responses.CoVepiT epitopes are selected from 11 viral protein targets and designed to cover all initial and...
-
Major expansion of clinical portfolio including initiation of clinical trials with Tedopi® in ovarian cancer, OSE-127/S95011 in ulcerative colitis, FR104 in renal transplant and an upcoming phase 1/2...
-
This clinical trial will be sponsored and conducted by the French oncology cooperative group ARCAGY-GINECO and supported by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.,...
-
CLEC-1, novel myeloid immune checkpoint for cancer immunotherapy limiting tumor cells phagocytosis and tumor antigen cross-presentation.BiCKI®-IL-7, bifunctional therapy targeting PD-1 and IL-7 to...